Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

Last week, AbbVie (ABBV) announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie's pipeline with the August 2024 acquisition of Cerevel Therapeutics, a neuroscience drugmaker, for around $8.7 billion. ABBV's Positive Parkinson's Study Data In the TEMPO-1 study, patients who received two fixed doses (5mg and 15mg) of once-daily tavapadon, a D1/D5 dopamine receptor partial agonist, for 2 ...